Impact of Depleting Therapeutic Monoclonal Antibodies on the Host Adaptive Immunity: A Bonus or a Malus?

Frontiers in Immunology - Switzerland
doi 10.3389/fimmu.2017.00950
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

The Practical Replacement of a Bonus-Malus System

ASTIN Bulletin
AccountingEconomicsEconometricsFinance
2001English

Effect of Kinase Inhibitors on the Therapeutic Properties of Monoclonal Antibodies

mAbs
AllergyImmunology
2015English

Confidence Intervals of the Premiums of Optimal Bonus Malus Systems

Scandinavian Actuarial Journal
UncertaintyEconomicsStatisticsEconometricsProbability
2017English

Bonus-Malus Kujoniert Ärzte Und Nährt Anwälte

MMW Fortschritte der Medizin
Medicine
2006English

Monoclonal Antibodies — A Proven and Rapidly Expanding Therapeutic Modality for Human Diseases

Protein & Cell
BiochemistryBiotechnologyDrug DiscoveryCell BiologyMedicine
2010English

Allowance for Cost of Claims in Bonus-Malus Systems

ASTIN Bulletin
AccountingEconomicsEconometricsFinance
1997English

Accounting for Individual Over-Dispersion in a Bonus-Malus Automobile Insurance System

ASTIN Bulletin
AccountingEconomicsEconometricsFinance
1999English

Optimal Bonus-Malus Systems Using Finite Mixture Models

ASTIN Bulletin
AccountingEconomicsEconometricsFinance
2014English

Therapeutic Potential of Inorganic Nanoparticles for the Delivery of Monoclonal Antibodies

Journal of Nanomaterials
Materials ScienceNanotechnologyNanoscience
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy